ArticleIJU case reports2026
Salvage Surgery for Primary Renal Pelvic Urothelial Carcinoma After Enfortumab Vedotin: A Case of Durable Remission With Nectin-4 Loss.
Article in IJU case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Salvage Surgery for Primary Renal Pelvic Urothelial Carcinoma After Enfortumab Vedotin: A Case of Durable Remission With Nectin-4 Loss.IJU case reports · 2026Article
- Pathologic Complete Response After Enfortumab Vedotin Plus Pembrolizumab in Node-positive Upper Tract Urothelial Carcinoma.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Enfortumab vedotin is a standard therapy for advanced urothelial carcinoma, but its efficacy may be limited by acquired resistance and spatial heterogeneity of Nectin-4 expression. Case Presentation: We report the case of a 76-year-old woman with cT3N2M0 left renal pelvic urothelial carcinoma that was treated with first-line chemotherapy, followed by pembrolizumab, and subsequently enfortumab vedotin. After 16 cycles of enfortumab vedotin, lymph node metastases remained shrunk, but isolated progression of the primary tumor occurred. Salvage nephroureterectomy was therefore performed, and the patient has remained recurrence-free for one year postoperatively. Immunohistochemistry showed a marked decline in Nectin-4 expression in the resected tumor compared with at the time of the initial biopsy. Conclusion: This case highlights the potential role of surgery for localized progression during enfortumab vedotin therapy. Nectin-4 reassessment may be considered selectively at decision-changing junctures when results are likely to alter management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.